Mavacamten Reduces LVOT Obstruction Risk, Enabling Transseptal Mitral Valve-in-Valve for Degenerated Bioprosthesis

Key Points

• To explore the effect of mavacamten on LVOT obstruction and its implications for TMVR.
• Short-term intervention with mavacamten
• Assessment of LVOT obstruction risk
• Examination of CT screening feasibility
• Potential application of transseptal mitral valve-in-valve method.
• Mavacamten reduces LVOT obstruction risk
• Facilitates a feasible TMVR pathway in selected patients
• Converts CT screening into a viable option for treatment.